|
| InsiderPie Expert Score
| P/E ratio
| Net margin
| ROA
| Net income per employee
|
| Danaher Corporation
|
72
/ 100
| 42
| 14.0%
| 4.1%
| €47.07K
|
| Intelligent Bio Solutions Inc.
|
50
/ 100
| -1
| -346.2%
| -128.1%
| -€180.29K
|
| Vimian Group AB (publ)
|
50
/ 100
| 81
| 5.6%
| 2.0%
| €18.90K
|
| Fulgent Genetics, Inc.
|
51
/ 100
| -12
| -16.8%
| -4.3%
| -€33.15K
|
| Lumibird SA
|
50
/ 100
| 26
| 3.1%
| 3.0%
| €12.48K
|
| NanoRepro AG
|
50
/ 100
| -2.1
| -55.9%
| -24.6%
| -€444.52K
|
| Exagen Inc.
|
50
/ 100
| -9
| -28.8%
| -28.9%
| -€69.30K
|
| Verici Dx plc
|
50
/ 100
| -0.23
| -368.2%
| -132.3%
| -€719.26K
|
| Proteome Sciences plc
|
50
/ 100
| -1.6
| -0.0%
| -63.5%
| -€186.43K
|
| Illumina, Inc.
|
61
/ 100
| 12
| 29.4%
| 20.7%
| €119.62K
|
| IDEXX Laboratories, Inc.
|
74
/ 100
| 43
| 24.4%
| 29.6%
| €76.43K
|
| Enzo Biochem, Inc.
|
48
/ 100
| -0.78
| -76.7%
| -33.2%
| -€143.86K
|
| Myriad Genetics, Inc.
|
50
/ 100
| -1.2
| -47.4%
| -58.3%
| -€124.85K
|
| Exact Sciences Corporation
|
55
/ 100
| -10
| -34.2%
| -17.3%
| -€124.26K
|
| Medpace Holdings, Inc.
|
63
/ 100
| 21
| 18.7%
| 26.6%
| €60.47K
|
| Standard BioTools Inc.
|
50
/ 100
| -3.4
| -78.2%
| -22.9%
| -€184.13K
|
| Waters Corporation
|
72
/ 100
| 31
| 22.1%
| 14.5%
| €76.63K
|
| Trinity Biotech plc
|
50
/ 100
| -0.38
| -51.6%
| -30.8%
| -€71.35K
|
| Meridian Bioscience, Inc.
|
50
/ 100
| -551
| -0.9%
| -0.6%
| -€3.34K
|
| Interpace Biosciences, Inc.
|
50
/ 100
| 0.64
| 11.4%
| 42.0%
| €39.80K
|
| Mettler-Toledo International Inc.
|
64
/ 100
| 30
| 21.5%
| 24.4%
| €44.23K
|
| Star Equity Holdings, Inc.
|
46
/ 100
| -0.99
| -9.7%
| -6.4%
| -€28.72K
|
| Precipio, Inc.
|
50
/ 100
| -9.1
| -8.8%
| -9.6%
| -€28.45K
|
| PerkinElmer, Inc.
|
52
/ 100
| 49
| 10.9%
| 2.4%
| €14.97K
|
| ANGLE plc
|
50
/ 100
| -1.5
| -497.0%
| -55.9%
| -€108.82K
|
| Biocept, Inc.
|
50
/ 100
| -0.013
| 1,015.8%
| -157.9%
| -€595.39K
|
| Synlab AG
|
50
/ 100
| 27
| 3.4%
| 1.9%
| €3.31K
|
| OPKO Health, Inc.
|
50
/ 100
| -5.9
| -26.7%
| -9.0%
| -€50.41K
|
| Bionano Genomics, Inc.
|
50
/ 100
| -0.15
| -271.0%
| -97.8%
| -€646.94K
|
| Aclaris Therapeutics, Inc.
|
50
/ 100
| -1.2
| -802.0%
| -71.2%
| -€1.88M
|
| Biocartis Group NV
|
50
/ 100
| -0.21
| -119.1%
| -117.2%
| -€251.66K
|
| IQVIA Holdings Inc.
|
49
/ 100
| 22
| 7.9%
| 4.3%
| €11.86K
|
| Diaceutics PLC
|
50
/ 100
| -29
| -6.2%
| -7.1%
| -€21.51K
|
| Neuronetics, Inc.
|
50
/ 100
| -4.8
| -43.5%
| -35.9%
| -€57.53K
|
| RadNet, Inc.
|
51
/ 100
| 1.5K
| 0.1%
| 0.1%
| €217.04
|
| Eurofins Scientific SE
|
51
/ 100
| 19
| 4.7%
| 5.3%
| €9.01K
|
| Lonza Group AG
|
51
/ 100
| 31
| 9.5%
| 6.9%
| €77.68K
|
| CareDx, Inc
|
52
/ 100
| 21
| 15.2%
| 11.6%
| €68.45K
|
| Invitae Corporation
|
50
/ 100
| -0.0038
| -299.1%
| -269.2%
| -€722.81K
|
| Twist Bioscience Corporation
|
54
/ 100
| -25
| -23.5%
| -13.2%
| -€78.72K
|
| Guardant Health, Inc.
|
63
/ 100
| -15
| -49.9%
| -31.1%
| -€176.57K
|
| Neogen Corporation
|
47
/ 100
| -0.94
| -119.3%
| -31.5%
| -€317.70K
|
| MDxHealth SA
|
50
/ 100
| -2.1
| -75.1%
| -35.2%
| -€161.82K
|
| DiaSorin S.p.A.
|
51
/ 100
| 26
| 16.0%
| 0.0%
| €59.40K
|
| Thermo Fisher Scientific Inc.
|
61
/ 100
| 23
| 15.3%
| 6.5%
| €45.21K
|
| Personalis, Inc.
|
49
/ 100
| -6.4
| -113.7%
| -35.3%
| -€341.63K
|
| Charles River Laboratories International, Inc.
|
50
/ 100
| -106
| -1.7%
| -0.9%
| -€3.16K
|
| Agilent Technologies, Inc.
|
57
/ 100
| 28
| 18.0%
| 10.0%
| €58.13K
|
| HTG Molecular Diagnostics, Inc.
|
50
/ 100
| -0.000011
| -324.3%
| -185.5%
| -€324.31K
|
